Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stan B Kaye

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2008
Reversal of drug resistance in ovarian cancer: where do we go from here?Stan B Kaye
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|October 20, 2005
Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistanceAlan Richardson, Stan B Kaye
Nature Reviews. Clinical Oncology|February 29, 2012
Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?Susana Banerjee, Stan B Kaye
Gynecologic Oncology|January 1, 2013
Identifying prognostic signatures in the blood of ovarian cancer patientsGerhardt Attard, Stan B Kaye
Current Opinion in Pharmacology|June 6, 2006
Expression profiling and individualisation of treatment for ovarian cancerRoshan Agarwal, Stan B Kaye
European Journal of Cancer (Oxford, England : 1990)|August 15, 2002
Ovarian cancer: progress and continuing controversies in managementCharlotte Moss, Stan B Kaye
Nature Reviews. Cancer|July 2, 2003
Ovarian cancer: strategies for overcoming resistance to chemotherapyRoshan Agarwal, Stan B Kaye
Expert Review of Anticancer Therapy|May 10, 2005
Docetaxel in the management of ovarian cancerSarah P Blagden, Stan B Kaye
Nature Reviews. Clinical Oncology|August 12, 2010
Making the best of PARP inhibitors in ovarian cancerSusana Banerjee, Stan B Kaye, Alan Ashworth
Expert Opinion on Investigational Drugs|April 7, 2010
Current treatment and clinical trials in ovarian cancerLiz Y Han, Emma Kipps, Stan B Kaye
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2008
Reversal of drug resistance in ovarian cancer: where do we go from here?Stan B Kaye
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|October 20, 2005
Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistanceAlan Richardson, Stan B Kaye
Nature Reviews. Clinical Oncology|February 29, 2012
Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?Susana Banerjee, Stan B Kaye
Gynecologic Oncology|January 1, 2013
Identifying prognostic signatures in the blood of ovarian cancer patientsGerhardt Attard, Stan B Kaye
Current Opinion in Pharmacology|June 6, 2006
Expression profiling and individualisation of treatment for ovarian cancerRoshan Agarwal, Stan B Kaye
European Journal of Cancer (Oxford, England : 1990)|August 15, 2002
Ovarian cancer: progress and continuing controversies in managementCharlotte Moss, Stan B Kaye
Nature Reviews. Cancer|July 2, 2003
Ovarian cancer: strategies for overcoming resistance to chemotherapyRoshan Agarwal, Stan B Kaye
Expert Review of Anticancer Therapy|May 10, 2005
Docetaxel in the management of ovarian cancerSarah P Blagden, Stan B Kaye
Nature Reviews. Clinical Oncology|August 12, 2010
Making the best of PARP inhibitors in ovarian cancerSusana Banerjee, Stan B Kaye, Alan Ashworth
Expert Opinion on Investigational Drugs|April 7, 2010
Current treatment and clinical trials in ovarian cancerLiz Y Han, Emma Kipps, Stan B Kaye
Pageof 8